Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

Herold, Michael; Schulze, Antina; Niederwieser, Dietger; Franke, Astrid; Fricke, Hans-Joerg; Richter, P; Freund, Mathias; Ismer, B.; Dachselt, Klaus; Boewer, C; Schirmer, Veronika; Weniger, J.; Pasold, Rita; Winkelmann, Cornelia; Klinkenstein, C.; Schulze, Manfred; Arzberger, H.; Bremer, K.; Hahnfeld, S.; Schwarzer, Andreas; Müller, Cornelia

doi:10.1007/s00432-005-0023-2

Cited by 102 publications

(69 citation statements)

References 14 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[24][25][26][27] Epidemiological data also support a survival benefit of newer therapies in some malignancies; data from the Cancer Registry of Norway indicate that the per-inhabitant use of vinorelbine from 1999 to 2005 was correlated inversely with the risk of death in patients with nonsmall cell lung cancer. 28 Data from the Surveillance, Epidemiology, and End Results Program in the United States also reveal improvements in the survival of patients with hematologic malignancies.…”

Section: Do Innovative Cancer Treatments Improve Survival?mentioning

confidence: 99%

Innovative cancer therapies

Khayat

2011

Cancer

View full text Add to dashboard Cite

The costs of cancer care are rising, and spending on expensive innovative anticancer agents is likely to come under scrutiny as health care payers are confronted by the challenge of resource limits in the face of infinite demand. Indirect costs account for the major part of total attributable costs of cancer and are dominated by the cost of mortality in individuals of working age (who therefore do not contribute to economic productivity). Although cancer is a leading cause of morbidity and premature mortality, in 2007, it was estimated that cancer accounted for only around 6% of the total health care costs in Europe. It is estimated that cancer drug costs constitute around 12% of total direct cancer costs and 5% of the costs of all drugs. Countries vary in their uptake of novel anticancer agents. However, even in France-a leading nation for the use of these agents-the costs of innovative anticancer drugs accounted for <0.6% of total health care expenditure in 2006. Population-level data suggest that novel therapies have contributed (together with advances in screening and other aspects of care) to improvements in survival from cancer. If this is the case, then the potential reduction in the associated indirect costs could exceed the direct costs associated with the uptake of innovative drug therapies. Further research is required to establish the costs and benefits of novel agents in routine practice.

show abstract

Section: Do Innovative Cancer Treatments Improve Survival?mentioning

confidence: 99%

Innovative cancer therapies

Khayat

2011

Cancer

View full text Add to dashboard Cite

show abstract

“…Only 16 patients enrolled on that study had MCL histology, but the overall response rate of 75% (CR 50%) in this subset supported studying this agent in randomized trials. Herold et al 34 replaced CY with bendamustine when they compared COP (CY, VCR and prednisone) with the BOP (bendamustine, VCR and prednisone) regimen in patients with indolent non-Hodgkin's lymphoma or MCL. The projected 5-year survival for responders reached statistical significance but other end points were similar between treatment groups.…”

Section: New Chemotherapy Agentsmentioning

confidence: 99%

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

Nabhan

Ragam

Bitran

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

The role of hematopoietic SCT (HSCT) in mantle cell lymphoma (MCL) remains controversial. Most studies that support the utility of this approach were small phase II single-institution studies with highly selected patient populations. Furthermore, recent evidence suggesting initial observation as opposed to immediate therapy in MCL, coupled with the availability of newer therapeutic agents, complicates the role of HSCT and argues for conducting large phase III studies. In this review, we discuss the limitation of current evidence and the lack of large definitive studies. We then analyze the data on HSCT in relapsed MCL and as a frontline approach propose applying the new prognostic index, MIPI (MCL International Prognostic Index), in the decision making.

show abstract

“…[21][22][23][24] Bendamustine, a new agent encompassing properties of both purine analogs and alkylating agents, has been used in this setting as part of combination therapy and has shown promising results. [25][26][27][28] More data are emerging on the use of thalidomide and lenalidomide, two multifunctional immunomodulatory agents, as second-line treatments. 29,30 Another promising new agent in this setting is temsirolimus, an analog of the immunosuppressant drug sirolimus (first known as rapamycin), which has shown efficacy in treating relapsed or refractory MCL.…”

Section: Relapsed or Refractory MCLmentioning

confidence: 99%

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

Samad¹,

Younes

2010

OTT

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a rare and aggressive subtype of lymphoma associated with a poor prognosis. Chemotherapy is the mainstay of frontline treatment for patients with this disease. Despite high response rates to combination chemotherapy regimens, the majority of patients relapse within a few years of treatment. Therefore, finding efficacious treatments for relapsed or refractory disease has become a growing area of clinical research. The mammalian target of rapamycin (mTOR) is responsible for integrating cell signals from growth factors, hormones, and nutrients and communicating energy status. Scientific research on aberrant molecular pathways in cancer has revealed that several proteins along the mTOR pathway may be upregulated in this and other types of lymphoma. Temsirolimus is the first mTOR inhibitor that has shown clinical efficacy in treating MCL that has relapsed after frontline treatments.

show abstract

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

Abstract: Bendamustine can efficaciously and safely replace cyclophosphamide, as used in standard COP therapy, for the treatment of patients with indolent NHL and mantle cell lymphoma. Long-term survival data suggest a clinically significant benefit for patients treated with BOP.

Cited by 102 publications

References 14 publications

Innovative cancer therapies

Innovative cancer therapies

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

Contact Info

Product

Resources

About